XPPen Partners with Annecy International Animation Film Festival to Launch the Inaugural XPPen Award for Graduation Films, Nurturing the Next-Gen Talent
LOS ANGELES, June 16, 2025 /PRNewswire/ -- XPPen, the leading digital art…
Phoenix to Host SEMICON West 2025 for the First Time, Showcasing Arizona’s Critical Role as a Semiconductor Manufacturing Hub
Event registration now open, with expanded programming and support from key Arizona…
Kia Tasman Blazes New Trail for Pickup Truck Segment with Exceptional OffRoad Ability
Kia’s first pickup truck is built to tackle both on- and off-road…
NYSE Content Advisory: Pre-Market update + Wall Street readies for key economic data
NEW YORK, June 16, 2025 /PRNewswire/ -- The New York Stock Exchange…
Ravin Group Wins ‘Outstanding Component Supplier for Railway Infrastructure’ at ET Infra Rail Show Awards 2025
MUMBAI, India, June 16, 2025 /PRNewswire/ -- Ravin Group, India's pioneering cable manufacturing…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
STL expands Data Centre portfolio to meet emerging requirements for AI data centres
- High-performance, comprehensive cabling and connectivity solutions and engineering services - Fully…
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Kia Wins Gold at PR Awards AsiaPacific 2025 for PR Communication Promoting Global Awareness of Ocean Plastic Cleanup
Kia Global PR Group wins Gold award in Environmental category at PR…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
